Figure 3From: Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study DAS28: Treatment difference between canakinumab groups and placebo (using last observation carried forward), by visit (intention-to-treat population). *p < 0.04 vs. placeboBack to article page